Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Teva commences enrolment for Parkinson’s drug trial

Teva commences enrolment for Parkinson’s drug trial

11th February 2013

Teva has announced the first patient has been enrolled for a phase IV study of Azilect, its approved therapy for Parkinson's disease patients.

The Moderato trial aims to evaluate the effect of Azilect on cognitive function in adult Parkinson's patients suffering from mild cognitive impairment and represents the largest trial conducted among this patient population to date.

Around 170 patients will be enrolled across 30 sites in the US and the study will last 24 weeks, with the aim of showing the product's potential efficacy in treating a condition for which there are no currently available therapies.

Dr Michael Hayden, president of global research and development and chief scientific officer for Teva Pharmaceutical Industries, said: "Moderato demonstrates Teva's ongoing commitment to research with Azilect and the development of products aimed at meeting the specific needs of the CNS community."

This week, it was also announced that Teva has appointed Dr Arie Belldegrun – director of the University of California, Los Angeles Institute of Urologic Oncology – as the newest member of its board.ADNFCR-8000103-ID-801538600-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.